Zacks Company Profile for Bio-Techne Corp (TECH : NSDQ) |
|
|
|
Company Description |
Bio-Techne Corporation is a global life sciences company. It develops, manufactures, and sells biotechnology products and clinical diagnostic controls. It provides proteins, such as cytokines, growth factors, and enzymes; antibodies, including polyclonal and monoclonal antibodies; immunoassays comprising quantikine kits; and clinical diagnostic immunoassay kits. The Company also offers flow cytometry products; natural and synthetic chemical compounds; hematology controls and calibrators; and hematology control products. Bio-Techne Corporation, formerly known as Techne Corporation, is headquartered in Minneapolis, Minnesota.
Number of Employees: 3,100 |
|
|
|
Price / Volume Information |
Yesterday's Closing Price: $54.41 |
Daily Weekly Monthly
 |
20 Day Moving Average: 1,833,246 shares |
Shares Outstanding: 156.77 (millions) |
Market Capitalization: $8,529.71 (millions) |
Beta: 1.39 |
52 Week High: $83.62 |
52 Week Low: $46.01 |
Short Interest Ratio: |
|
% Price Change |
% Price Change Relative to S&P 500 |
4 Week |
5.59% |
1.63% |
12 Week |
13.12% |
-4.85% |
Year To Date |
-24.46% |
-29.26% |
|
|
|
|
|
|
|
General Corporate Information |
Officers
Kim Kelderman - President; Chief Executive Officer and Director
Robert V. Baumgartner - Chairman of the Board and Director
James Hippel - Executive Vice President and Chief Financial Offic
Shane Bohnen - Senior Vice President; General Counsel & Corp. Sec
Rupert Vessey - Director
|
|
Peer Information
Bio-Techne Corp (CORR.)
Bio-Techne Corp (RSPI)
Bio-Techne Corp (CGXP)
Bio-Techne Corp (BGEN)
Bio-Techne Corp (GTBP)
Bio-Techne Corp (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 09073M104
SIC: 2836
|
|
Fiscal Year
Fiscal Year End: June
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/06/25
|
|
Share - Related Items
Shares Outstanding: 156.77
Most Recent Split Date: 11.00 (4.00:1)
Beta: 1.39
Market Capitalization: $8,529.71 (millions)
|
|
|
|
|
|
EPS Information |
Dividend Information |
Analyst Coverage: No |
Dividend Yield: 0.59% |
Current Fiscal Quarter EPS Consensus Estimate: $0.38 |
Indicated Annual Dividend: $0.32 |
Current Fiscal Year EPS Consensus Estimate: $1.85 |
Payout Ratio: 0.19 |
Number of Estimates in the Fiscal Year Consensus: 5.00 |
Change In Payout Ratio: -0.03 |
Estmated Long-Term EPS Growth Rate: 11.38% |
Last Dividend Paid: 05/19/2025 - $0.08 |
Next EPS Report Date: 08/06/25 |
|
|
|
|